Zobrazeno 1 - 10
of 606
pro vyhledávání: '"endostar"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
In the management of advanced non-squamous non-small cell lung cancer (NSCLC) without driver gene mutations, the current therapeutic strategies encompass chemotherapy, chemotherapy combined with anti-angiogenic therapy, and chemotherapy combined with
Externí odkaz:
https://doaj.org/article/811b7ffcf7154db9916149264082ae4a
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
ObjectiveTo evaluate the effectiveness and safety of concurrent chemoradiotherapy using Endostar continuous infusion for treating oesophageal squamous cell carcinoma (OSCC).MethodA total of 62 patients with oesophageal carcinoma were divided into thr
Externí odkaz:
https://doaj.org/article/cdbedb1abd434bedb553fcc90a260f4b
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background CCRT is presently the standard treatment for LA-NSCLC. RP is one of the main obstacles to the completion of thoracic radiation therapy, resulting in limited survival benefits in NSCLC patients. This research aims to explore the ro
Externí odkaz:
https://doaj.org/article/7b4ebcf357f6402fbde6cb3e51fdd981
Autor:
Yufei Wang, Hong Ren
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Background Endostar, an anti-angiogenic drug, has been approved for treating non-small cell lung cancer (NSCLC). At present, endostar combined with radiotherapy or chemotherapy has achieved ideal results in the treatment of some tumors, but
Externí odkaz:
https://doaj.org/article/b3d27c1a18a64a96902fa7106ac18f92
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Malignant pleural effusion (MPE) is one of the common complications of lung cancer. The quality of life and prognoses for MPE patients are significantly compromised. Controlling the production of MPE can relieve patients’ symptoms, improve their qu
Externí odkaz:
https://doaj.org/article/92d9d534b266474b80925d7b5e9602b0
Autor:
Bing Han, Yanrong Kang, Haiji Wang, Jian Wang, Rong Shen, Shuai Liu, Lu Lu, Zhigang Sun, Nan Zhang
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Endostar is a strong angiogenesis inhibitor that is effective in treating non-small cell lung cancer (NSCLC), but the effect of Endostar in the treatment of patients with EGFR-TKI-resistant NSCLC remains unclear. We evaluated the
Externí odkaz:
https://doaj.org/article/90e7a16f2ed44e5d81b4db2cafd53892
Publikováno v:
Open Medicine, Vol 18, Iss 1, Pp 87-108 (2023)
Bronchoscopy has been widely used for the therapy of lung cancer. This study aimed to evaluate the therapeutic efficacy and adverse reactions of bronchoscopic intratumoral injection of endostar and cisplatin in patients with lung squamous cell carcin
Externí odkaz:
https://doaj.org/article/55f6aa609863491a8b1fbf9a562f59a7
Autor:
Wei Jiang, Jing Liang, Wei Sun, Wenhui Li, Jin Gao, Hui Wang, Wei Zhou, Lixiang Aa, Luhua Wang
Publikováno v:
Aging and Cancer, Vol 4, Iss 1, Pp 41-47 (2023)
Abstract Introduction This study aims to compare the real‐world effectiveness and safety of Endostar in combination with chemotherapy in the treatment of advanced non‐small cell lung cancer (NSCLC) in different age groups. Methods Electronic medi
Externí odkaz:
https://doaj.org/article/d1b926e714cb4c419eff1ccc2ae15521
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background and objectives Trastuzumab is an important targeted drug for HER2-positive gastric cancer. The treatment efficacy of a more cost-effective and accessible trastuzumab biosimilar, HLX02, was not well investigated, especially when co
Externí odkaz:
https://doaj.org/article/0449132438c74918bda62f68475f25ff
Publikováno v:
International Journal of Nanomedicine, Vol Volume 17, Pp 4791-4805 (2022)
Ying Yang,1 Ning Wang,2 XinXin Tian,1 XiaoLi Wang,1 Jing Yang,1 XiGang Leng,1 HaiLing Zhang1 1Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Biomaterials, Tianjin, Pe
Externí odkaz:
https://doaj.org/article/cd23df9b72eb4ffc8a474645a8f7cad2